CANSINO BIOLOGICS INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 50.41 CNY | -1.45% |
|
-3.13% | -32.35% |
| 05-21 | Cansino Biologics Invests 160 Million Yuan in China Bohai Bank’s Structured Deposits | MT |
| 04-29 | CanSino Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
ETFs positioned on CanSino Biologics Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.31% | 1 M€ | -15.71% | - | |
| 0.03% | 3 M€ | +2.90% | - | |
| 0.00% | 112 M€ | +4.59% | - | |
| 0.00% | 32 M€ | +7.50% | - | |
| 0.00% | 7 M€ | +0.11% | - |
CanSino Biologics Inc is a clinical-stage vaccine company in China. The Company's products include Ad5-EBOV vaccine used for Ebola virus, MCV2 and MCV4 vaccines for meningococcus, PBPV vaccine used for pneumococcal and the recombinant novel coronavirus vaccine. Its products are mainly used in meningitis, diphtheria pertussis tetanus (DPT) and pneumonia.
Sector
Pharmaceuticals
Calendar
2024-08-22
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
20.97
CNY
Average target price
25.66
CNY
Spread / Average Target
+22.37%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -2.15% | 90.02B | |
| -0.66% | 39.15B | |
| -15.83% | 31.71B | |
| +62.42% | 26.47B | |
| -21.68% | 14.34B | |
| -8.73% | 12.89B | |
| -10.32% | 11.18B | |
| -45.77% | 10.97B | |
| +3.45% | 8.94B |
- Stock Market
- Equities
- 6185 Stock
- 688185 Stock
- Funds and ETFs CanSino Biologics Inc.
